SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
9 references·3 citing·42 second hop
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial (2007)Cost-effectiveness analysis of anastrozol…What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)What Is the Price of Life and…Economic Evaluation in Health Care: Merging Theory with Practice (2002)Economic Evaluation in Health…Systematic Overview of Cost-Utility Assessments in Oncology (2000)Systematic Overview of Cost-U…One Thousand Health-Related Quality-of-Life Estimates (2000)One Thousand Health-Related Q…Accounting for future costs in medical cost-effectiveness analysis (1997)Accounting for future costs i…Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness in Health …Costs, effects and C/E‐ratios alongside a clinical trial (1994)Costs, effects and C/E‐ratios…Markov Models in Medical Decision Making (1993)Markov Models in Medical Deci…Measurement of health state utilities for economic appraisal (1986)Measurement of health state u…Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? (2014)Do Value Thresholds for Oncol…Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial (2007)Cost-effectiveness analysis o…Economic burden associated with breast cancer recurrence (2006)Economic burden associated wi…Social Choice and Individual Values. (1951)Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life (1989)Decisions with Multiple Objectives: Preferences and Value Tradeoffs. (1994)Conducting Discrete Choice Experiments to Inform Healthcare Decision Making (2008)Theory of games and economic behavior (2019)EuroQol - a new facility for the measurement of health-related quality of life (1990)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Health Care Economic Analyses and Value-Based Medicine (2003)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)Health Utilities Using the EQ-5D in Studies of Cancer (2007)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)The MOS 36-ltem Short-Form Health Survey (SF-36) (1992)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making (2004)A review of health utilities using the EQ-5D in studies of cardiovascular disease (2010)Protected Values and Omission Bias (1999)Willingness to Pay for a Quality-adjusted Life Year (2000)Interpreting the Results of Cost-Effectiveness Studies (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)A Guide to Simulation (1983)Handling Uncertainty in Cost-Effectiveness Models (2000)Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions (2004)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)The NICE Cost-Effectiveness Threshold (2008)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma (2017)Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer (2018)Indivisible labor and the business cycle (1985)Medical Care Costs: How Much Welfare Loss? (1992)Cost-effectiveness of Treatments for Major Depression in Primary Care Practice (1998)How to Calculate Indirect Costs in Economic Evaluations (1998)The Human Capital Model of the Demand for Health (1999)EQ-SD: a measure of health status from the EuroQol Group (2001)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Review of guidelines for good practice in decision-analytic modelling in health technology assessment (2004)The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations (2006)State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 (2012)An Introduction to Markov Modelling for Economic Evaluation (1998)
this work references cited by second hop

References

  • 1996Cost-Effectiveness in Health and Medicine7,192 cited
  • 1993Markov Models in Medical Decision Making2,411 cited
  • 1986Measurement of health state utilities for economic appraisal2,204 cited
  • 1994Costs, effects and C/E‐ratios alongside a clinical trial963 cited
  • 2002Economic Evaluation in Health Care: Merging Theory with Practice721 cited
  • 2000One Thousand Health-Related Quality-of-Life Estimates662 cited
  • 2003What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?588 cited
  • 1997Accounting for future costs in medical cost-effectiveness analysis444 cited
  • 2000Systematic Overview of Cost-Utility Assessments in Oncology296 cited

Cited by

  • 2014Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?73 cited
  • 2006Economic burden associated with breast cancer recurrence66 cited
  • 2007Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial61 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work